{"organizations": [], "uuid": "ab9cba3812c0123df376b952461c462e513b2d5a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/InVitroDiagnosticsFinancing", "section_title": "In Vitro Diagnostics Financing from Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530636?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522In%2520Vitro%2520Diagnostics%2522)%2520%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "", "title": "Castle Biosciences starts off Series F round with $11.7mm tranche", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Castle Biosciences starts off Series F round with $11.7mm tranche", "spam_score": 0.0, "site_type": "news", "published": "2015-08-19T02:40:00.000+03:00", "replies_count": 0, "uuid": "ab9cba3812c0123df376b952461c462e513b2d5a"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530636?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522In%2520Vitro%2520Diagnostics%2522)%2520%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Castle Biosciences starts off Series F round with $11.7mm tranche", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Castle Biosciences starts off Series F round with $11.7mm tranche Deal Date: Jul-01-2015 / Deal # 201530636 Executive Summary \nCastle Biosciences Inc. (molecular diagnostics for cancer) brought in $11.7mm through the first tranche of its $20mm Series F round expected to close by the end of the third quarter. Industry Ventures led and   backers HealthQuest Capital, Mountain Group Partners, and 14 other investors. Proceeds will fund continued work on the company's Decision-Dx Melanoma gene test to identify metastatic risk in patients with Stage I and II cutaneous melanoma.", "external_links": [], "published": "2015-08-19T02:40:00.000+03:00", "crawled": "2015-08-19T08:59:38.717+03:00", "highlightTitle": ""}